Expanding the Criteria for Nipple-Sparing Mastectomy in Patients With Poor Prognostic Features

Priya Jadeja, Richard Ha, Christine Rohde, Jeffrey Ascherman, Robert Grant, Christine Chin, Eileen Connolly, Kevin Kalinsky, Sheldon M. Feldman, Bret Taback

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: In this study we aimed to review the outcomes of nipple-sparing mastectomy (NSM) in the setting of expanded criteria: previous breast surgery/irradiation, neoadjuvant chemotherapy (NAC), post-NSM irradiation, and to assess conversion to acceptable criteria after NAC. Patients and Methods: In this single-institution institutional review board-approved retrospective review, we identified patients who underwent NSM after previous breast intervention or NAC from January 2010 to February 2017. Clinicopathologic features, previous breast surgeries, response rate, complications, and recurrences were recorded. Results: Sixty-three patients underwent 106 NSMs. Among 63 patients, 39 (61.9%) received NAC, 30 (47.6%) previous lumpectomy, 4 (6.3%) with cosmetic implants, 4 (6.3%) with mastopexy, 5 (7.9%) with previous radiation therapy, and 21 (33%) underwent post-NSM radiation therapy. Transient epidermolysis occurred in 24 patients (38.1%), with 16 patients (66.6%) having complete flap recovery and nipple loss in 8 patients (12.6%). All 10 patients with central disease on pre-NAC imaging converted to acceptable criteria, with 9 having successful NSM. At mean 67.2-month follow-up, 56 patients (88.9%) were disease-free, 5 (7.9%) experienced a systemic recurrence, and 2 (3.2%) a local recurrence. Conclusion: NSM is oncologically acceptable in this patient cohort. Patients with large central tumors who undergo NAC should be reconsidered after completion of chemotherapy because many might convert to successful nipple-areolar preservation.

Original languageEnglish (US)
JournalClinical Breast Cancer
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

Nipples
Mastectomy
Drug Therapy
Breast
Recurrence
Radiotherapy
Segmental Mastectomy
Research Ethics Committees
Cosmetics

Keywords

  • Breast cancer
  • Breast surgery
  • Conversion after chemotherapy
  • Neoadjuvant chemotherapy
  • Nipple-sparing mastectomy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jadeja, P., Ha, R., Rohde, C., Ascherman, J., Grant, R., Chin, C., ... Taback, B. (Accepted/In press). Expanding the Criteria for Nipple-Sparing Mastectomy in Patients With Poor Prognostic Features. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2017.08.010

Expanding the Criteria for Nipple-Sparing Mastectomy in Patients With Poor Prognostic Features. / Jadeja, Priya; Ha, Richard; Rohde, Christine; Ascherman, Jeffrey; Grant, Robert; Chin, Christine; Connolly, Eileen; Kalinsky, Kevin; Feldman, Sheldon M.; Taback, Bret.

In: Clinical Breast Cancer, 01.01.2017.

Research output: Contribution to journalArticle

Jadeja, Priya ; Ha, Richard ; Rohde, Christine ; Ascherman, Jeffrey ; Grant, Robert ; Chin, Christine ; Connolly, Eileen ; Kalinsky, Kevin ; Feldman, Sheldon M. ; Taback, Bret. / Expanding the Criteria for Nipple-Sparing Mastectomy in Patients With Poor Prognostic Features. In: Clinical Breast Cancer. 2017.
@article{d2fad72b9ad24ce5ba3df0c226f68f48,
title = "Expanding the Criteria for Nipple-Sparing Mastectomy in Patients With Poor Prognostic Features",
abstract = "Background: In this study we aimed to review the outcomes of nipple-sparing mastectomy (NSM) in the setting of expanded criteria: previous breast surgery/irradiation, neoadjuvant chemotherapy (NAC), post-NSM irradiation, and to assess conversion to acceptable criteria after NAC. Patients and Methods: In this single-institution institutional review board-approved retrospective review, we identified patients who underwent NSM after previous breast intervention or NAC from January 2010 to February 2017. Clinicopathologic features, previous breast surgeries, response rate, complications, and recurrences were recorded. Results: Sixty-three patients underwent 106 NSMs. Among 63 patients, 39 (61.9{\%}) received NAC, 30 (47.6{\%}) previous lumpectomy, 4 (6.3{\%}) with cosmetic implants, 4 (6.3{\%}) with mastopexy, 5 (7.9{\%}) with previous radiation therapy, and 21 (33{\%}) underwent post-NSM radiation therapy. Transient epidermolysis occurred in 24 patients (38.1{\%}), with 16 patients (66.6{\%}) having complete flap recovery and nipple loss in 8 patients (12.6{\%}). All 10 patients with central disease on pre-NAC imaging converted to acceptable criteria, with 9 having successful NSM. At mean 67.2-month follow-up, 56 patients (88.9{\%}) were disease-free, 5 (7.9{\%}) experienced a systemic recurrence, and 2 (3.2{\%}) a local recurrence. Conclusion: NSM is oncologically acceptable in this patient cohort. Patients with large central tumors who undergo NAC should be reconsidered after completion of chemotherapy because many might convert to successful nipple-areolar preservation.",
keywords = "Breast cancer, Breast surgery, Conversion after chemotherapy, Neoadjuvant chemotherapy, Nipple-sparing mastectomy",
author = "Priya Jadeja and Richard Ha and Christine Rohde and Jeffrey Ascherman and Robert Grant and Christine Chin and Eileen Connolly and Kevin Kalinsky and Feldman, {Sheldon M.} and Bret Taback",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.clbc.2017.08.010",
language = "English (US)",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",

}

TY - JOUR

T1 - Expanding the Criteria for Nipple-Sparing Mastectomy in Patients With Poor Prognostic Features

AU - Jadeja, Priya

AU - Ha, Richard

AU - Rohde, Christine

AU - Ascherman, Jeffrey

AU - Grant, Robert

AU - Chin, Christine

AU - Connolly, Eileen

AU - Kalinsky, Kevin

AU - Feldman, Sheldon M.

AU - Taback, Bret

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: In this study we aimed to review the outcomes of nipple-sparing mastectomy (NSM) in the setting of expanded criteria: previous breast surgery/irradiation, neoadjuvant chemotherapy (NAC), post-NSM irradiation, and to assess conversion to acceptable criteria after NAC. Patients and Methods: In this single-institution institutional review board-approved retrospective review, we identified patients who underwent NSM after previous breast intervention or NAC from January 2010 to February 2017. Clinicopathologic features, previous breast surgeries, response rate, complications, and recurrences were recorded. Results: Sixty-three patients underwent 106 NSMs. Among 63 patients, 39 (61.9%) received NAC, 30 (47.6%) previous lumpectomy, 4 (6.3%) with cosmetic implants, 4 (6.3%) with mastopexy, 5 (7.9%) with previous radiation therapy, and 21 (33%) underwent post-NSM radiation therapy. Transient epidermolysis occurred in 24 patients (38.1%), with 16 patients (66.6%) having complete flap recovery and nipple loss in 8 patients (12.6%). All 10 patients with central disease on pre-NAC imaging converted to acceptable criteria, with 9 having successful NSM. At mean 67.2-month follow-up, 56 patients (88.9%) were disease-free, 5 (7.9%) experienced a systemic recurrence, and 2 (3.2%) a local recurrence. Conclusion: NSM is oncologically acceptable in this patient cohort. Patients with large central tumors who undergo NAC should be reconsidered after completion of chemotherapy because many might convert to successful nipple-areolar preservation.

AB - Background: In this study we aimed to review the outcomes of nipple-sparing mastectomy (NSM) in the setting of expanded criteria: previous breast surgery/irradiation, neoadjuvant chemotherapy (NAC), post-NSM irradiation, and to assess conversion to acceptable criteria after NAC. Patients and Methods: In this single-institution institutional review board-approved retrospective review, we identified patients who underwent NSM after previous breast intervention or NAC from January 2010 to February 2017. Clinicopathologic features, previous breast surgeries, response rate, complications, and recurrences were recorded. Results: Sixty-three patients underwent 106 NSMs. Among 63 patients, 39 (61.9%) received NAC, 30 (47.6%) previous lumpectomy, 4 (6.3%) with cosmetic implants, 4 (6.3%) with mastopexy, 5 (7.9%) with previous radiation therapy, and 21 (33%) underwent post-NSM radiation therapy. Transient epidermolysis occurred in 24 patients (38.1%), with 16 patients (66.6%) having complete flap recovery and nipple loss in 8 patients (12.6%). All 10 patients with central disease on pre-NAC imaging converted to acceptable criteria, with 9 having successful NSM. At mean 67.2-month follow-up, 56 patients (88.9%) were disease-free, 5 (7.9%) experienced a systemic recurrence, and 2 (3.2%) a local recurrence. Conclusion: NSM is oncologically acceptable in this patient cohort. Patients with large central tumors who undergo NAC should be reconsidered after completion of chemotherapy because many might convert to successful nipple-areolar preservation.

KW - Breast cancer

KW - Breast surgery

KW - Conversion after chemotherapy

KW - Neoadjuvant chemotherapy

KW - Nipple-sparing mastectomy

UR - http://www.scopus.com/inward/record.url?scp=85030031471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030031471&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2017.08.010

DO - 10.1016/j.clbc.2017.08.010

M3 - Article

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

ER -